ATE400267T1 - Zusammensetzung zur potenzierung von krebs- chemotherapeutika - Google Patents

Zusammensetzung zur potenzierung von krebs- chemotherapeutika

Info

Publication number
ATE400267T1
ATE400267T1 AT01964398T AT01964398T ATE400267T1 AT E400267 T1 ATE400267 T1 AT E400267T1 AT 01964398 T AT01964398 T AT 01964398T AT 01964398 T AT01964398 T AT 01964398T AT E400267 T1 ATE400267 T1 AT E400267T1
Authority
AT
Austria
Prior art keywords
potentifying
composition
cancer chemotherapeutics
vitamin
cancer
Prior art date
Application number
AT01964398T
Other languages
English (en)
Inventor
Raxit Jariwalla
Original Assignee
Ester C Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ester C Company filed Critical Ester C Company
Application granted granted Critical
Publication of ATE400267T1 publication Critical patent/ATE400267T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01964398T 2000-09-01 2001-08-24 Zusammensetzung zur potenzierung von krebs- chemotherapeutika ATE400267T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/654,377 US6468980B1 (en) 2000-09-01 2000-09-01 Methods and compositions for potentiating cancer chemotherapeutic agents

Publications (1)

Publication Number Publication Date
ATE400267T1 true ATE400267T1 (de) 2008-07-15

Family

ID=24624611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964398T ATE400267T1 (de) 2000-09-01 2001-08-24 Zusammensetzung zur potenzierung von krebs- chemotherapeutika

Country Status (15)

Country Link
US (1) US6468980B1 (de)
EP (1) EP1286674B1 (de)
JP (1) JP2004508335A (de)
KR (1) KR20030019297A (de)
AT (1) ATE400267T1 (de)
AU (1) AU8525401A (de)
CA (1) CA2389602A1 (de)
CY (1) CY1108787T1 (de)
DE (1) DE60134740D1 (de)
DK (1) DK1286674T3 (de)
ES (1) ES2309085T3 (de)
MX (1) MXPA02004327A (de)
PT (1) PT1286674E (de)
TR (1) TR200201192T1 (de)
WO (1) WO2002020023A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878744B2 (en) * 1999-02-05 2005-04-12 Oxycal Laboratories, Inc. Vitamin C compositions
CN1197561C (zh) * 2001-07-03 2005-04-20 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗损及软骨的疾病的药物中的用途
AU2003269967A1 (en) 2003-08-13 2005-03-10 Oxycal Laborataries, Inc. Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes
EP3542785A1 (de) * 2007-01-31 2019-09-25 Rutgers, The State University of New Jersey Gesteuerte freisetzung von wirkstoffen in der haut
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
TR2022000209A2 (tr) 2022-01-07 2022-02-21 Oezge Gueven Ozoni̇ze c-vi̇tami̇ni̇ i̇çeren bi̇r anti̇-kanser i̇laci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249632A4 (de) * 1985-12-05 1988-06-20 American Biotechnology Antitumormittel vom athracyclintyp mit l-ascorbinsäure.
GB8810173D0 (en) * 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
WO1990012571A1 (en) * 1989-04-07 1990-11-01 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin c
JPH08291075A (ja) * 1995-04-20 1996-11-05 Showa Denko Kk 癌転移阻害剤
EP0875246A1 (de) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmazeutische Zusammensetzung aus Ascorbinsäurederivate zur Behandlung von Krebs
PT982990E (pt) * 1998-02-06 2007-01-31 Ester C Company Composições líquidas estáveis de ascorbato de cálcio e métodos de preparação e utilização
CN1165301C (zh) * 1999-08-30 2004-09-08 奥克斯可尔实验室公司 组合物在制备治疗癌症的药物中的用途

Also Published As

Publication number Publication date
AU8525401A (en) 2002-03-22
CA2389602A1 (en) 2002-03-14
JP2004508335A (ja) 2004-03-18
EP1286674A1 (de) 2003-03-05
US6468980B1 (en) 2002-10-22
KR20030019297A (ko) 2003-03-06
DE60134740D1 (de) 2008-08-21
PT1286674E (pt) 2008-08-21
ES2309085T3 (es) 2008-12-16
EP1286674B1 (de) 2008-07-09
MXPA02004327A (es) 2002-11-07
CY1108787T1 (el) 2014-04-09
EP1286674A4 (de) 2005-12-21
TR200201192T1 (tr) 2003-05-21
WO2002020023A1 (en) 2002-03-14
DK1286674T3 (da) 2008-11-03

Similar Documents

Publication Publication Date Title
BR0215405A (pt) Composições e processos de uso de collajolie
BR0113798A (pt) Derivados de resorcinol
TR200000782T2 (tr) Resorsinol türevleri.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
MXPA04004347A (es) Nuevos fotoindicadores difuncionales.
ES2176212T3 (es) Eteres de fosfonooximetilicos o metiltiometilicos de derivados de taxano como agentes antitumorales.
MXPA03007140A (es) Derivados de carbolina.
DE602004012083D1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
BR0209149A (pt) Ftalazinonas
BR9912327A (pt) Inibidores da uroquinase
CY1108787T1 (el) Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
HRP20030154B1 (en) Preparation of risperidone
ATE496109T1 (de) Umsetzungsprodukte von mercaptobenzothiazolen, mercaptothiazolinen und mercaptobenzimidazolen mit epoxiden als schmiermitteladditive
TR200100455T2 (tr) Nimesulid içeren topikal farmasötik bileşimler
TR200102742T2 (tr) Rezorsinol türevleri
SE9903290D0 (sv) Novel compounds
TR200302193T4 (tr) Kombinasyon kemoterapisi.
PT1192284E (pt) Curtimenta de couro
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
DE60134814D1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
DE60133600D1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
MXPA03001440A (es) Compuestos de trioxepano novedosos.
DE60237756D1 (de) Zusammensetzungen zur verhinderung der thrombozytenaggregation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1286674

Country of ref document: EP

REN Ceased due to non-payment of the annual fee